Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort
- PMID: 36946230
- DOI: 10.1093/bjd/ljad076
Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort
Conflict of interest statement
Conflicts of interest R.A.S. has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol Myers Squibb, Myriad Genetics and GlaxoSmithKline. J.F.T. has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis. S.N.L. and A.E.C. contributed equally to this article.
Comment in
-
Which patients with melanoma are a priority for monitoring to detect new primary melanoma?Br J Dermatol. 2023 Jul 7;189(1):e3. doi: 10.1093/bjd/ljad125. Br J Dermatol. 2023. PMID: 37067919 No abstract available.
Comment on
-
Which patients with melanoma are a priority for monitoring to detect new primary melanoma?Br J Dermatol. 2023 Jul 7;189(1):e3. doi: 10.1093/bjd/ljad125. Br J Dermatol. 2023. PMID: 37067919 No abstract available.
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
